ArticleInfectious diseases & clinical microbiology2026
Seroprotection after a Standard Three-Dose Hepatitis B Vaccination Series in Immune-Mediated Rheumatic Diseases: A Retrospective Observational Study.
Article in Infectious diseases & clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate seroprotection rates after a standard three-dose hepatitis B vaccination series in adults with immune-mediated rheumatic diseases (IMRDs) and to identify clinical and treatment-related factors associated with vaccine response in routine clinical practice. Materials and Methods: This retrospective observational study was conducted between January 2022 and August 2024. Adults with rheumatologist-confirmed IMRDs who were susceptible to hepatitis B virus (HBV) at baseline and who underwent quantitative hepatitis B surface antibody (anti-HBs) testing 4-8 weeks after receipt of the third vaccine dose were included. Results: Of 260 eligible patients, 161 completed the standard three-dose hepatitis B vaccination series, and post-vaccination anti-HBs results were available for 152 patients included in the final analysis. Seroprotection was achieved in 110 (72.4%) patients. In multivariable logistic regression analysis, longer disease duration and systemic corticosteroid exposure were independently associated with lower odds of achieving seroprotection. Age, sex, smoking status, body mass index, and comorbidity burden were not independently associated with vaccine response. Conclusion: In adults with IMRDs, approximately three-quarters achieved seroprotection after standard hepatitis B vaccination. Longer disease duration and systemic corticosteroid exposure were independently associated with reduced serologic response. These findings highlight the importance of timely vaccination and consideration of cumulative immunosuppressive burden in routine clinical practice. Graphic Abstract: Graphic Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.